1Steven H, Elias C, Nancy I.H, et al. WHO Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues[M]. Lyon : IARC Press, 2008 : 2330 244.
2Lenburg M E,Sinha A, Failer D V, et al. Tumor specific and Proliferation specific Gene Expression Typifies Murine Transgenie B Cell Lymphomagenesis[J]. J Biol Chem, 2007,282(7) : 4803-4811.
3Alizadeh A A,Eisen M B,Davis R E,et al. Distinct Types of Diffuse Large B-cell Lyrnphoma Identified by Gene Expression Profiling[J]. Nature,2000,403(6769) :503-511.
4Davis R E,Brown K D,Siebenlist U,et al. Constitutive Nuclear Factorκ:B Activity is Required for Survival of Activated B Cell- like Diffuse Large B Cell Lymphoma Cells[J]. J Exp Med, 2001,194(12):1861- 1874.
5Rosenwald A,Wright G,Chan W C,et al. The Use of Molecular Profiling to Prodecit Survival afte Chemotherapy for Diffuse Large B Cell Lymphoma[J]. N Engl Med, 2002,346 (25) : 1937-1947.
6Tagawa H, Suguro M, Tsuzuki S,et al. Comparison of Genome Profiles for Identification of Distinct Subgroups of Diffuse Large B cell Lymphoma[J]. Blood,2005,106:1770- 1777.
7Hans C P,Weisen Burger D D,Greiner T C,et al. Contirmation of the Molecular Classification of Diffuse Large B Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray [J]. Blood,2004,103(1) :275- 282.
8Yamaguehi M, Nakamura N, Suzuki R, et al. De Novo CD5 + Diffuse Large B-cell Lymphoma: Results of a Detailed Clinico pathological Review in 120 Patients[J]. Haematological,2008, 93(8) : 1195-202.
9Hyo R,Tomita N,Takeuchi K, et al. The Therapeutic Effect of Rituximab on CDS-positive and CDS-negative Diffuse Large B- cell Lymphoma[J]. Hematol Oncol, 2009,[ Epub ahead of print].
10Monti S,Savage K J, Kutok J L, et al. Molecular Profiling of Diffuse Large B-cell Lymphoma Identifies Robust Subtypes Including one Characterized by Host Inflammatory Response [J]. Blood,2005,105(5):1851-1861.
4Zhang H, Kobayashi R, Galaktionov K, et al. P19Skpl and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinas[J]. Cell, 1995,82(6) :915 - 925.
5Cunningham MA, Zhu Q, Hammond JM. Foxola can alter cell cycle progression by regulating the nuclear localization of p27kip in granulosa cells [J]. Mol Endocrinol,2004,18 (7): 1756- 1767.
6Seki R, Okamura T, Koga H, et al. Prognostic significance of the F- Box protein Skp2 expression in diffuse large B-cel lymphoma[ J]. Am J Hematol,2003,73(4) :230 - 235.
7Traub F, Mengel M, Lack HJ, et al. Prognostic impact of Skp2 and p27 in human breast cancer[J]. Breast Cancer Res Treat, 2006, 99 (2):185- 191.
8Harada K, Supriatno, Kawagnchi S, et al. High expression of S-phase kinase associated protein2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation[J]. Anticancer Res, 2005,25(3c) :2471 - 2475.
9Takanami I. The prognostic value of overexpression of Skp2 mRNA in non-small cell lung cancer[J]. Oncol Rep, 2005,13(4) :727 - 731.
10Woenckhaus C, Maile S, Uffmann S, et al. Expression of Skp2 and p27KIPI in naevi and malignant melanoma of the skin and its relation to clinical outcome[J]. Histol Histopathol, 2005,20(2) :501 - 508.
4Katna R,Shet T,Sengar M,et al.Clinicopathologic study and outcome analysis of thyroid lymphomas :experience from a tertiary cancer center [J ].Head Neck, 2013,35 (2) : 165-171.
5Rosenberg S A.Validity of the Ann Arbor staging classifi- cation for the non-Hodgkin's lymph omas[J].Cancer Treat Rep, 1977,61 (6) : 1023-1027.
6Graft Baker A, Sosa J A,Roman S A.Primary thyroid lym- phoma:a review of recent developments in diagnosis and histology -driven treatment [ J ].Curt Opin Oncol, 2010,22 ( 1 ) : 17-22.
7Hwang Y C,Kim T Y,Kim W B,et al.Clinical character- istics of primary thyroid lymphoma in Koreans [J].Endocr J,2009,56(3). 399-405.
8Basu S,Li G,Bural G,et al.Fluorodeoxyglucose positron emission tomography(FDG-PET) and PET/computed to- mography imaging characteristics of thyroid lymphoma and their potential clinical utility [J].Acta Radiol,2009,50 (2) :201-204.
9Sakorafas G H,Kokkoris P,Farley D R.Primary thyroid lymphoma (correction of lympoma) : diagnostic and thera- peutic dilemmas [ J J.Surg Oncol, 2010,19 (4) : e 124-e 129.
10Onal C,Li Y X,Miller R C,et al.Treatment results and prognostic factor in primary thyroid lymphoma patients: a rare cancer network study[J].Ann Oncol,2011,22( 1 ) : 156-164.
